1. Interstitial Lung Disease in India. Keep Searching and You'll Keep Finding.Am J Respir Crit Care Med. 2017 Mar 15;195(6):714-715.
  2. Mobility patterns of persons at risk for drug-resistant tuberculosis in Mumbai, India. Int J Tuberc Lung Dis. 2016 Dec;20(12):1633-1638.
  3. Imatinib-induced pleural effusion: A case report. J Postgrad Med. 2016 Nov 16. doi: 10.4103/0022-3859.194227.
  4. Corrigendum to "Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables" . Int J Mycobacteriol. 2016 Sep;5(3):370-372.
  5. Therapeutic choices in rifampicin-resistant tuberculosis. Lancet Infect Dis.2016 Nov;16(11):1220-1221
  6. Importance of Therapeutic Drug Monitoring of Rifampicin. J Assoc Physicians India. 2016 Aug;64(8):68-72.
  7. Who will teach the teachers: An analysis of the inhaler technique of Indian patients and health care providers in a tertiary health care centre.Lung India. 2016 Sep-Oct;33(5):493-5.
  8. Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai. Lung India. 2016 May-Jun;33(3):253-6.
  9. BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers. Clin Infect Dis. 2016 May 15;62 Suppl 3:S262-7.
  10. Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables. Int J Mycobacteriol. 2016 Mar;5(1):1-6.
  11. Poncet's Arthritis in a Patient with Multidrug-Resistant Tuberculosis. Indian J Chest Dis Allied Sci. 2015 Jul-Sep;57(3):195-8.
  12. Eosinophilic Granulomatosis with Polyangitis Presenting as Cardiac Tamponade. Indian J Chest Dis Allied Sci. 2015 Apr-Jun;57(2):121-3.
  13. Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations. Int J Tuberc Lung Dis. 2015 Oct;19(10):1227-9.
  14. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2015 Sep 24;13:237
  15. Response to Dr Daley's article: Do not ignore the private sector. Indian J Tuberc. 2015 Jan;62(1):54-5.
  16. Tuberculosis in India. BMJ. 2015 Mar 23;350:h1080. doi: 10.1136/bmj.h1080.
  17. Defining multidrug-resistant tuberculosis: correlating GenoType MTBDRplus assay results with minimum inhibitory concentrations.
  18. Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis. Lung India. 2015 Jan-Feb;32(1):50-2.
  19. Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. Tuberculosis (Edinb). 2015 Mar;95(2):137-41.
  20. Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai. Lung India. 2014 Oct;31(4):336-41.
  21. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India. Int J Tuberc Lung Dis. 2014 Nov;18(11):1315-8.